Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Joseph M. Rocco, Elizabeth Laidlaw, Bonnie Yates, Brett Schroeder, Emily Limerick, William T. Johnson, Joseph H. Oved, Frances Galindo, Whitney Ewing, Courtney Fitzhugh, Maura Manion, Andrea Lisco, Steven Holland, Nirali N. Shah, Irini Sereti

Blood (2024) 144 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2024-210363

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Tommaso Balestra, Camilo Arenas Merizalde, Robert K Chen, John Roach, Brian Bowser, Rachelle Salomon, Anthony Welch, Bonnie Yates, Kristin Schaller, Michael R Verneris, Susanne H.C. Baumeister, Emily M. Hsieh, M. Eric Kohler, Katherine Tarlock, Steven M. Devine, Richard Aplenc, Nirali N. Shah, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 369.

https://doi.org/10.1182/blood-2024-211517

Published: 2024

Journal Articles

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

Blood (2024) 144 (Supplement 1): 7203.

https://doi.org/10.1182/blood-2024-201984

Published: 2024

Journal Articles

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Alexandra Dreyzin, Yihua Cai, Kyu Lee Han, Michaela Prochazkova, Jennifer Webb, Keri Toner, Kathryn Bushnell, Bonnie Yates, Ping Jin, David F. Stroncek, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2024-199264

Published: 2024

Journal Articles

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Blood (2024) 144 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2024-202335

Published: 2024

Journal Articles

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Adam Lamble, Emily M. Hsieh, Samuel John, Gregory Dolan, Hongyan Liu, Lee Chen, Jennifer Sheppard, Amanda M. DiNofia, Colleen Annesley, Stephan A. Grupp, Deepa Bhojwani, Rebecca A. Gardner, Lia Gore, Susan R Rheingold, Nirali N. Shah, Michael A. Pulsipher

Blood (2024) 144 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2024-202027

Published: 2024

Journal Articles

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Jacinta Davis, JuanCarlos Balandrán, Katharina Hayer, Sisi Zheng, Zhiwei Ang, Evelyn Liu, Bonnie Yates, Nirali N. Shah, Iannis Aifantis, Andrei Thomas-Tikhonenko

Blood (2024) 144 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2024-208185

Published: 2024

Journal Articles

Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies

Aalia N. Khan, Jayant S. Goda, Sweety Asija, Atharva Karulkar, Pranoti Palkar, Ambalika Chowdury, Ankesh K. Jaiswal, Deepti Phadnis, Shreshtha Shah, Afrin Firfiray, Juber Pendhari, Pranali Patil, Nirali N. Shah, Manju Sengar, Hasmukh Jain, Rahul Purwar

Blood (2024) 144 (Supplement 1): 4809.

https://doi.org/10.1182/blood-2024-203862

Published: 2024

Journal Articles

Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Alexandra E. Kovach, Sara K. Silbert, Annie Luong, Gerald Lu, Michael Lu, Hao-Wei Wang, Karen M Chisholm, Andrew Doan, Deepa Bhojwani, Adam Lamble, Nirali N. Shah, Chintan Parekh, Gordana Raca, Brent L. Wood

Blood (2024) 144 (Supplement 1): 2799.

https://doi.org/10.1182/blood-2024-198961

Published: 2024

Journal Articles

CARdinal signs of variant ICANS

Juliane Gust, Nirali N. Shah

Blood (2024) 144 (13): 1352–1354.

https://doi.org/10.1182/blood.2024025664

Published: 2024

Journal Articles

How I treat post-immunotherapy relapsed B-ALL

Adam J. Lamble, Alexandra E Kovach, Nirali N Shah

Blood blood.2024024517.

https://doi.org/10.1182/blood.2024024517

Published: 2024

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Blood (2023) 142 (Supplement 1): 257.

https://doi.org/10.1182/blood-2023-177594

Published: 2023

Journal Articles

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Susan R Rheingold, Lingyun Ji, Lia Gore, Xinxin Xu, Deepa Bhojwani, Nirali N. Shah, Elizabeth A. Raetz, Mignon L. Loh, Maureen M. O'Brien

Blood (2023) 142 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2023-183103

Published: 2023

Journal Articles

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

Alka Dwivedi, Lynn Fu, Chris Daniel Chien, Marie Pouzolles, Nirali N. Shah, Naomi Taylor

Blood (2023) 142 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2023-190357

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne

Blood (2023) 142 (Supplement 1): 4862.

https://doi.org/10.1182/blood-2023-180990

Published: 2023

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies

Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

CARdinal signs of variant ICANS

How I treat post-immunotherapy relapsed B-ALL

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility

Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia

Engineering Off-the-Shelf Gamma Delta CAR T Cells for the Treatment of Acute Myeloid Leukemia

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only